Flutemetamol F 18

(Vizamyl®)

Vizamyl®

Drug updated on 12/19/2023

Dosage FormInjection (intravenous; 150 MBq/mL (4.05 mCi/mL)
Drug ClassRadioactive diagnostic agents
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline.

Product Monograph / Prescribing Information

Document TitleYearSource
Vizamyl (flutemetamol F 18) Prescribing Information.2020GE Healthcare, Medi-Physics, Inc., Arlington Heights, IL

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
136Subjects
F: 48%
M: 52%
2021European Journal of Nuclear Medicine and Molecular Imaging

Sex Distribution:

F:48%
M:52%
136Subjects

Year:

2021

Source:European Journal of Nuclear Medicine and Molecular Imaging

Clinical Practice Guidelines